Alfa Oncology is pleased to announce the launch of its new CRO services specific to brain tumor research.
New York, United States, 30th Jan 2024, King NewsWire – Alfa Oncology, a leading biotechnology company specializing in oncology research and development, is pleased to announce the launch of its new Contract Research Organization (CRO) services specific to brain tumor research. This launch comes as a strategic move following the successful implementation of Alfa Oncology’s innovative tumor microenvironment (TME) technology platform.
Alfa Oncology’s cutting-edge TME technology platform consists of a series of separate business platforms, including microfluidics technology platform, sequencing technology platform, mass spectrometry technology platform, imaging technology platform, immune cell technology platform, stem cell technology platform, animal model technology platform, and animal experiment platform, etc. The TME center technology platform encompasses a wide range of capabilities such as single-cell omics of TME, animal model customization for TME, in vivo pharmacology targeting TME, and cell biology research. More importantly, this platform can freely combine technologies according to different research purposes to support various single or integrated projects.
Building on this success, Alfa Oncology is now extending its expertise to focus on the challenging field of brain tumor research. Due to the complexity and resistance to traditional therapies, brain tumors present unique challenges. Responding to these challenges, Alfa Oncology provides neoantigen manufacturing and antibody drug development services for brain tumors through its proven technology platform. These include PD-1/PD-L1 antibodies for immune checkpoint inhibitors, antibodies that inhibit the CD161-CLEC2D pathway, and 124I-8H9 monoclonal antibodies targeting B7-H3. In addition to antibody drug development, the company also offers basic and preclinical research services, exosome development services as well as small molecule drug development services for brain tumors.
With the launch of its brain tumor-related CRO services, Alfa Oncology aims to accelerate the discovery and development of novel treatment options for patients suffering from brain tumors. These services will offer comprehensive support for academic researchers, pharmaceutical companies, and clinical trial sponsors throughout all stages of preclinical and clinical research.
About Alfa Oncology
Alfa Oncology is a comprehensive biotechnology company headquartered in the United States, focusing on research on the tumor microenvironment, brain tumor research, and neoantigen development. The company is dedicated to providing professional tumor-related research services to customers all over the world, aimed to help customers solve project problems or develop new research directions in an all-round way, and accelerate their research speed. Alfa Oncology can also tailor solutions for clients according to their scientific research needs.
Media Contact
Organization: Alfa Oncology
Contact Person: Thassia C.
Website: https://www.alfaoncology.com/
Email: Send Email
State: New York
Country: United States
Release Id: 3001249327
The post Alfa Oncology Launches Brain Tumor-Related CRO Services Following Its TME Tech Platform appeared first on King NewsWire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.